Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT)

NCT04476199 is registered in ClinicalTrials.gov with Gruppo Italiano Trapianto di Midollo Osseo as lead sponsor.

NCT NCT04476199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT)
Lead sponsor
Gruppo Italiano Trapianto di Midollo Osseo
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 9, 2019
Completion date
June 30, 2025
Enrollment
100 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia